| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5514646 | LILLY | Insulin analogs modified at position 29 of the B chain |
May, 2013
(11 years ago) | |
| US5474978 | LILLY | Insulin analog formulations |
Jun, 2014
(9 years ago) | |
| US5461031 | LILLY | Monomeric insulin analog formulations |
Jun, 2014
(9 years ago) | |
| US5747642 | LILLY | Monomeric insulin analog formulations |
Jun, 2014
(9 years ago) | |
| US7291132 | LILLY | Medication dispensing apparatus with triple screw threads for mechanical advantage |
Aug, 2024
(3 months from now) | |
Humalog Mix 75/25 Kwikpen is owned by Lilly.
Humalog Mix 75/25 Kwikpen contains Insulin Lispro Protamine Recombinant; Insulin Lispro Recombinant.
Humalog Mix 75/25 Kwikpen has a total of 5 drug patents out of which 4 drug patents have expired.
Expired drug patents of Humalog Mix 75/25 Kwikpen are:
- US5514646
- US5474978
- US5461031
- US5747642
Humalog Mix 75/25 Kwikpen was authorised for market use on 22 December, 1999.
Humalog Mix 75/25 Kwikpen is available in injectable;injection dosage forms.
Humalog Mix 75/25 Kwikpen can be used as use for the treatment of hyperglycemia, treatment of diabetes mellitus.
The generics of Humalog Mix 75/25 Kwikpen are possible to be released after 09 August, 2024.
Market Authorisation Date: 22 December, 1999
Treatment: Use for the treatment of hyperglycemia; Treatment of diabetes mellitus
Dosage: INJECTABLE;INJECTION
HUMALOG MIX 75/25 KWIKPEN family patents
